Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 66

1.

Diagnostic Leukapheresis Enables Reliable Transcriptomic Profiling of Single Circulating Tumor Cells to Characterize Inter-Cellular Heterogeneity in Terms of Endocrine Resistance.

Reinhardt F, Franken A, Meier-Stiegen F, Driemel C, Stoecklein NH, Fischer JC, Niederacher D, Ruckhaeberle E, Fehm T, Neubauer H.

Cancers (Basel). 2019 Jun 28;11(7). pii: E903. doi: 10.3390/cancers11070903.

2.

From in vitro to ex vivo: subcellular localization and uptake of graphene quantum dots into solid tumors.

Kersting D, Fasbender S, Pilch R, Kurth J, Franken A, Ludescher M, Naskou J, Hallenberger A, Gall CV, Mohr CJ, Lukowski R, Raba K, Jaschinski S, Esposito I, Fischer JC, Fehm T, Niederacher D, Neubauer H, Heinzel T.

Nanotechnology. 2019 Sep 27;30(39):395101. doi: 10.1088/1361-6528/ab2cb4. Epub 2019 Jun 26.

PMID:
31239418
3.

Detection of circulating tumor cells in colorectal cancer patients using the GILUPI CellCollector: results from a prospective, single-center study.

Dizdar L, Fluegen G, van Dalum G, Honisch E, Neves RP, Niederacher D, Neubauer H, Fehm T, Rehders A, Krieg A, Knoefel WT, Stoecklein NH.

Mol Oncol. 2019 Jul;13(7):1548-1558. doi: 10.1002/1878-0261.12507. Epub 2019 Jun 17.

4.

Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products.

Franken A, Driemel C, Behrens B, Meier-Stiegen F, Endris V, Stenzinger A, Niederacher D, Fischer JC, Stoecklein NH, Ruckhaeberle E, Fehm T, Neubauer H.

Clin Chem. 2019 Apr;65(4):549-558. doi: 10.1373/clinchem.2018.296814. Epub 2019 Feb 8.

PMID:
30737205
5.

Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting.

Fehm TN, Meier-Stiegen F, Driemel C, Jäger B, Reinhardt F, Naskou J, Franken A, Neubauer H, Neves RPL, van Dalum G, Ruckhäberle E, Niederacher D, Rox JM, Fischer JC, Stoecklein NH.

Cytometry A. 2018 Dec;93(12):1213-1219. doi: 10.1002/cyto.a.23669.

PMID:
30551262
6.

EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients.

de Wit S, Manicone M, Rossi E, Lampignano R, Yang L, Zill B, Rengel-Puertas A, Ouhlen M, Crespo M, Berghuis AMS, Andree KC, Vidotto R, Trapp EK, Tzschaschel M, Colomba E, Fowler G, Flohr P, Rescigno P, Fontes MS, Zamarchi R, Fehm T, Neubauer H, Rack B, Alunni-Fabbroni M, Farace F, De Bono J, IJzerman MJ, Terstappen LWMM.

Oncotarget. 2018 Nov 2;9(86):35705-35716. doi: 10.18632/oncotarget.26298. eCollection 2018 Nov 2.

7.

Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.

Schultz S, Bartsch H, Sotlar K, Petat-Dutter K, Bonin M, Kahlert S, Harbeck N, Vogel U, Seeger H, Fehm T, Neubauer HJ.

BMC Med Genomics. 2018 Sep 20;11(1):80. doi: 10.1186/s12920-018-0403-5.

8.

Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap).

Andree KC, Mentink A, Zeune LL, Terstappen LWMM, Stoecklein NH, Neves RP, Driemel C, Lampignano R, Yang L, Neubauer H, Fehm T, Fischer JC, Rossi E, Manicone M, Basso U, Marson P, Zamarchi R, Loriot Y, Lapierre V, Faugeroux V, Oulhen M, Farace F, Fowler G, Sousa Fontes M, Ebbs B, Lambros M, Crespo M, Flohr P, de Bono JS.

Int J Cancer. 2018 Nov 15;143(10):2584-2591. doi: 10.1002/ijc.31752. Epub 2018 Sep 19.

9.

Magnetic resonance imaging findings of high-grade ductal carcinoma in situ of the male breast: A case report.

Reinhardt F, Mathys B, Reinecke P, Neubauer H, Fehm T, Mohrmann S.

SAGE Open Med Case Rep. 2018 Jun 12;6:2050313X18781727. doi: 10.1177/2050313X18781727. eCollection 2018.

10.

Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.

Huebner H, Fasching PA, Gumbrecht W, Jud S, Rauh C, Matzas M, Paulicka P, Friedrich K, Lux MP, Volz B, Gass P, Häberle L, Meier-Stiegen F, Hartkopf A, Neubauer H, Almstedt K, Beckmann MW, Fehm TN, Ruebner M.

BMC Cancer. 2018 Feb 20;18(1):204. doi: 10.1186/s12885-018-4115-1.

11.

Membrane-initiated effects of Serelys® on proliferation and apoptosis of human breast cancer cells.

Seeger H, Ruan X, Neubauer H, Brucker S, Mueck AO.

Gynecol Endocrinol. 2018 Apr;34(4):353-356. doi: 10.1080/09513590.2017.1407751. Epub 2017 Nov 27.

PMID:
29179606
12.

Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?

Reinhardt F, Franken A, Fehm T, Neubauer H.

Tumour Biol. 2017 Nov;39(11):1010428317731511. doi: 10.1177/1010428317731511. Review.

PMID:
29129161
13.

Quantifying HER-2 expression on circulating tumor cells by ACCEPT.

Zeune L, van Dalum G, Decraene C, Proudhon C, Fehm T, Neubauer H, Rack B, Alunni-Fabbroni M, Terstappen LWMM, van Gils SA, Brune C.

PLoS One. 2017 Oct 30;12(10):e0186562. doi: 10.1371/journal.pone.0186562. eCollection 2017.

14.

Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells.

Willibald M, Bayer G, Stahlhut V, Poschmann G, Stühler K, Gierke B, Pawlak M, Seeger H, Mueck AO, Niederacher D, Fehm T, Neubauer H.

Oncotarget. 2017 Aug 2;8(42):72480-72493. doi: 10.18632/oncotarget.19819. eCollection 2017 Sep 22.

15.

A Novel Workflow to Enrich and Isolate Patient-Matched EpCAMhigh and EpCAMlow/negative CTCs Enables the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer.

Lampignano R, Yang L, Neumann MHD, Franken A, Fehm T, Niederacher D, Neubauer H.

Int J Mol Sci. 2017 Aug 31;18(9). pii: E1885. doi: 10.3390/ijms18091885.

16.

High Level of Progesteron Receptor Membrane Component 1 (PGRMC 1) in Tissue of Breast Cancer Patients is Associated with Worse Response to Anthracycline-Based Neoadjuvant Therapy.

Willibald M, Wurster I, Meisner C, Vogel U, Seeger H, Mueck AO, Fehm T, Neubauer H.

Horm Metab Res. 2017 Aug;49(8):595-603. doi: 10.1055/s-0043-113635. Epub 2017 Jul 12.

PMID:
28701017
17.

Enrichment, Isolation and Molecular Characterization of EpCAM-Negative Circulating Tumor Cells.

Lampignano R, Schneck H, Neumann M, Fehm T, Neubauer H.

Adv Exp Med Biol. 2017;994:181-203. doi: 10.1007/978-3-319-55947-6_10. Review.

PMID:
28560675
18.

Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer.

Ruan X, Zhang Y, Mueck AO, Willibald M, Seeger H, Fehm T, Brucker S, Neubauer H.

Menopause. 2017 Feb;24(2):203-209. doi: 10.1097/GME.0000000000000739.

PMID:
27749742
19.

A bead-based western for high-throughput cellular signal transduction analyses.

Treindl F, Ruprecht B, Beiter Y, Schultz S, Döttinger A, Staebler A, Joos TO, Kling S, Poetz O, Fehm T, Neubauer H, Kuster B, Templin MF.

Nat Commun. 2016 Sep 23;7:12852. doi: 10.1038/ncomms12852.

20.

Alterations of the exo- and endometabolite profiles in breast cancer cell lines: A mass spectrometry-based metabolomics approach.

Willmann L, Schlimpert M, Hirschfeld M, Erbes T, Neubauer H, Stickeler E, Kammerer B.

Anal Chim Acta. 2016 Jun 21;925:34-42. doi: 10.1016/j.aca.2016.04.047. Epub 2016 Apr 28.

PMID:
27188315

Supplemental Content

Loading ...
Support Center